echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur Urol Focus: Robot-Assisted Versus Laparoscopic Radical Prostate Surgery: 12-Month Results from the Multicenter Randomized Controlled LAP-01 Trial

    Eur Urol Focus: Robot-Assisted Versus Laparoscopic Radical Prostate Surgery: 12-Month Results from the Multicenter Randomized Controlled LAP-01 Trial

    • Last Update: 2022-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Previously, the LAP-01 trial conducted by researchers from the University of Leipzig in Germany and other units demonstrated that robotic-assisted laparoscopic radical prostatectomy (RARP) was superior to conventional laparoscopic radical prostatectomy (LRP) in terms of urinary incontinence after 3 months


    In the present trial, they further compared RARP and LRP for voiding capacity, sexual intercourse, and oncological outcomes at 12 months of follow-up


    RARP and LRP were further compared for voiding capacity, sexual intercourse, and oncological outcomes at 12-month follow-up


    In this multicenter, randomized, patient-blind controlled trial, patients referred for radical prostatectomy at four hospitals in Germany were randomized 3:1 to receive RARP or LRP


    Figure 1 Urinary incontinence after 3, 6 and 12 months of follow-up

    Figure 1 Urinary incontinence after 3, 6 and 12 months of follow-up



    Robotic assistance provides better functional results in specific areas Robotic assistance provides better functional results in specific areas

     

    Original source:

    Original source:

    Jens-Uwe Stolzenburg , Sigrun Holze , Vinodh-Kumar-Adithyaa Arthanareeswaran et al.


    Jens-Uwe Stolzenburg , Sigrun Holze , Vinodh-Kumar-Adithyaa Arthanareeswaran et al.
    Robotic-assisted Versus Laparoscopic Radical Prostatectomy: 12-month Outcomes of the Multicentre Randomised Controlled LAP-01 Trial.
    Eur Urol Focus.
    Feb 2022.


    Leave a Comment
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.